Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

Official title:

Change of Serum Wnt2 or Wnt4 and the Relationship With Hs-CRP，cTnI and Prognosis in Patients With Acute Coronary Syndrome

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03342131
• Other study ID #: PJ-KS-KY-2017-104(X)
• Status: Enrolling by invitation
• Phase: N/A
• First received: November 9, 2017
• Last updated: February 6, 2018
• Start date: September 29, 2017
• Est. completion date: March 29, 2019

Study information

• Verified date: September 2017
• Source: The First Affiliated Hospital of Dalian Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to find the change of serum wnt effectory moleculars and the association with Hs-CRP，cTnI and Prognosis in Patients with Acute Coronary Syndrome.

Description:

It has been reported that wnt effecory moleculars (wnt2, wnt4, wnt11,wnt10b, DKK1, DKK2) increased in myocardium at acute phase after myocardium infarction in animal experiment. These moleculars can be detected in serum or plasma from human subjects. However, there is few relevant studies about wnt2 and wnt4 concentration in patients with acute coronary syndrome. This study valuates the serum wnt2 and wnt4 concentration in patients with acute coronary syndrome. It will possibly enable to find the relationship between serum wnt2 or wnt4 concentration and Hs-CRP, cTnI and prognosis in patients with Acute Coronary Syndrome.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 450
• Est. completion date: March 29, 2019
• Est. primary completion date: September 29, 2018
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

.diagnosed as acute coronary syndrome, including STEMI and NST-ACS.

• with left ventricular ejection fraction(LVEF)>=45%

• written informed consents are obtained

• admitted within 24 hours after chest pain attacked

Exclusion Criteria:

• • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy

• complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction

• with acute or chronic infection, surgery or trauma in the last month

• secondary hypertension, severe liver dysfunction,severe renal insufficiency

• with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Intervention

Other:
• Circulating wnt 2 and wnt 4 concentration
Blood (150 each group) is obtained into ethylenediaminetetraacetic acid(EDTA) tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission. Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Dalian Medical University	Dalian	Liaoning

Sponsors (2)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Dalian Medical University	Fudan University

Country where clinical trial is conducted

China, 

References & Publications (6)

Aisagbonhi O, Rai M, Ryzhov S, Atria N, Feoktistov I, Hatzopoulos AK. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis Model Mech. 2011 Jul;4(4):469-83. doi: 10.1242/dmm.006510. Epub 2011 F — View Citation

Alexandrovich A, Arno M, Patient RK, Shah AM, Pizzey JA, Brewer AC. Wnt2 is a direct downstream target of GATA6 during early cardiogenesis. Mech Dev. 2006 Apr;123(4):297-311. Epub 2006 Apr 18. — View Citation

Caprioli A, Villasenor A, Wylie LA, Braitsch C, Marty-Santos L, Barry D, Karner CM, Fu S, Meadows SM, Carroll TJ, Cleaver O. Wnt4 is essential to normal mammalian lung development. Dev Biol. 2015 Oct 15;406(2):222-34. doi: 10.1016/j.ydbio.2015.08.017. Epu — View Citation

Goodwin AM, D'Amore PA. Wnt signaling in the vasculature. Angiogenesis. 2002;5(1-2):1-9. Review. — View Citation

Pérez Castrillón JL, San Miguel A, Vega G, Abad L, Andres Domingo M, Gonzalez Sagredo M, de Luis D, Duenas-Laita A. Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin. Int J Cardiol. 2010 Nov 5;145(1):164-5. doi: 10.1 — View Citation

Wang L, Hu XB, Zhang W, Wu LD, Liu YS, Hu B, Bi CL, Chen YF, Liu XX, Ge C, Zhang Y, Zhang M. Dickkopf-1 as a novel predictor is associated with risk stratification by GRACE risk scores for predictive value in patients with acute coronary syndrome: a retro — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum wnt2 and wnt4 concentration	Serum wnt2 and wnt4 concentration in ng/ml	12 months
Secondary	Relationship between wnt2 or wnt4 and high sensitive C reaction protein (hs-CRP) concentration	Correlation of wnt2 and wnt4 with hs-CRP concentration	12 months
Secondary	Relationship between wnt2 or wnt4 and Troponin-I (Tn-I) concentration	Correlation of wnt2 and wnt4 with Tn-I concentration	12 months
Secondary	MACEs during 12-month follow-up	Association of wnt2 or wnt4 concentration with prognosis	12 months